EDITAS MEDICINE, INC. (EDIT) Spending and interest coverage
- R&D / revenue · 12 months: Value 180.74%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 18.41%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 180.74% | Research and development expense / revenue. Period ending 2026-06-30. $84.96M ÷ $47.01M × 100 ≈ 180.74% |
| Stock-based compensation / revenue · 12 months | 18.41% | Share-based compensation / revenue. Period ending 2026-06-30. $8.65M ÷ $47.01M × 100 ≈ 18.41% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 84.96M USD | Research and Development Expense |
| Revenue | 47.01M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 8.65M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -75.86M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $84.96M | $47.01M | $8.65M | $-75.86M | (m) | 180.74% | 18.41% | (m) | (m) |
| 2026-03-31 | $80.96M | $38.69M | $9.12M | $-108.85M | (m) | 209.24% | 23.58% | (m) | (m) |
| 2025-12-31 | $89.95M | $40.52M | $10.00M | $-160.01M | (m) | 222.00% | 24.68% | (m) | (m) |
| 2025-09-30 | $111.16M | $46.38M | $11.89M | $-198.85M | (m) | 239.66% | 25.64% | (m) | (m) |
| 2025-06-30 | $139.02M | $38.90M | $14.46M | $-239.97M | (m) | 357.38% | 37.18% | (m) | (m) |
| 2025-03-31 | $177.05M | $35.84M | $16.81M | $-260.32M | (m) | 494.05% | 46.91% | (m) | (m) |
| 2024-12-31 | $199.25M | $32.31M | $21.42M | $-251.15M | (m) | 616.60% | 66.28% | (m) | (m) |
| 2024-09-30 | $220.19M | $61.76M | $22.74M | $-228.52M | (m) | 356.53% | 36.82% | (m) | (m) |
| 2024-06-30 | $213.06M | $67.03M | $22.67M | $-213.02M | (m) | 317.85% | 33.82% | (m) | (m) |
| 2024-03-31 | $188.63M | $69.41M | $22.88M | $-185.21M | (m) | 271.78% | 32.96% | (m) | (m) |
| 2023-12-31 | $177.65M | $78.12M | $19.80M | $-169.18M | (m) | 227.40% | 25.34% | (m) | (m) |
| 2023-09-30 | $160.09M | $24.61M | $19.82M | $-208.66M | (m) | 650.52% | 80.52% | (m) | (m) |
| 2023-06-30 | $160.91M | $19.32M | $20.97M | $-216.02M | (m) | 833.02% | 108.55% | (m) | (m) |
| 2023-03-31 | $174.79M | $22.79M | $22.37M | $-226.16M | (m) | 766.87% | 98.15% | (m) | (m) |
| 2022-12-31 | $174.96M | $19.71M | $29.29M | $-225.95M | (m) | 887.57% | 148.61% | (m) | (m) |
| 2022-09-30 | $160.51M | $25.64M | $31.59M | $-204.11M | (m) | 625.90% | 123.17% | (m) | (m) |
| 2022-06-30 | $148.45M | $31.80M | $35.72M | $-185.85M | (m) | 466.83% | 112.32% | (m) | (m) |
| 2022-03-31 | $138.55M | $25.82M | $42.63M | $-187.01M | (m) | 536.67% | 165.11% | (m) | (m) |
| 2021-12-31 | $142.51M | $25.54M | $43.40M | $-193.15M | (m) | 557.89% | 169.90% | (m) | (m) |
| 2021-09-30 | $166.46M | $24.49M | $41.41M | $-217.41M | (m) | 679.59% | 169.08% | (m) | (m) |
| 2021-06-30 | $171.11M | $81.14M | $37.25M | $-169.17M | (m) | 210.89% | 45.91% | (m) | (m) |
| 2021-03-31 | $165.36M | $91.51M | $29.14M | $-145.11M | (m) | 180.71% | 31.84% | (m) | (m) |
| 2020-12-31 | $158.00M | $90.73M | $23.16M | $-134.84M | (m) | 174.13% | 25.52% | (m) | (m) |
| 2020-09-30 | $131.28M | $91.60M | $23.82M | $-108.39M | (m) | 143.32% | 26.00% | (m) | (m) |
| 2020-06-30 | $120.07M | $32.60M | $24.53M | $-151.97M | (m) | 368.26% | 75.24% | (m) | (m) |
| 2020-03-31 | $115.63M | $24.18M | $25.61M | $-156.28M | (m) | 478.09% | 105.88% | (m) | (m) |
| 2019-12-31 | $96.90M | $20.53M | $27.24M | $-140.92M | (m) | 471.96% | 132.69% | (m) | (m) |
| 2019-09-30 | $81.30M | $14.37M | $27.25M | $-127.75M | (m) | 565.94% | 189.71% | (m) | (m) |
| 2019-06-30 | $76.05M | $25.04M | $27.39M | $-109.42M | (m) | 303.73% | 109.41% | (m) | (m) |
| 2019-03-31 | $85.20M | $30.08M | $27.93M | $-113.43M | (m) | 283.24% | 92.84% | (m) | (m) |
| 2018-12-31 | $90.65M | $31.94M | $26.60M | $-113.73M | (m) | 283.85% | 83.28% | (m) | (m) |
| 2018-09-30 | $97.88M | (m) | $28.33M | $-123.92M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $100.84M | (m) | $26.10M | $-134.41M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $85.44M | (m) | $24.09M | $-120.86M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $83.16M | (m) | $23.36M | $-119.93M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $83.57M | (m) | $19.07M | $-122.47M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $74.01M | (m) | $18.29M | $-116.89M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $67.12M | (m) | $18.48M | $-109.98M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $56.98M | (m) | $16.88M | $-97.19M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $18.85M | (m) | $3.51M | $-35.31M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $5.07M | (m) | $55.00K | $-12.72M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |